ClinicalTrials.gg
CompletedNCT05922917PIVCOUpdated Oct 30, 2026

Pulsed-field Ablation in Patients With Persistent Atrial Fibrillation

An interventional study of pulsed-field ablation in Persistent Atrial Fibrillation and Pulsed-field Ablation, sponsored by České Budějovice Hospital. Completed at 3 sites in Czechia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by České Budějovice Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
518
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies in Atrial Fibrillation with a site in Czechia — 39 open to participants now, 50 under way, 6 of them phase 3. Atrial Fibrillation · Czechia.

Enrollment
39th of 153
518 · median 200
Started
2023
with 14 others
No phase
96 of 184
23 open now
Registered
145th of 184
by date

Among the 184 studies in Atrial Fibrillation with a site in Czechia, this one is the 39th largest by enrollment of the 153 interventional ones that give a count, is one of 15 that started in 2023, is one of 96 with no phase, and was the 145th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

39 of the 184 studies in Atrial Fibrillation with a site in Czechia are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Atrial Fibrillation with a site in Czechia, or all of them as a file.
02

Study summary

Since a new method called pulsed-field ablation (PFA) has emerged, allowing significantly simpler, safer, and faster creation of ablative lesions in paroxysmal AF and PsAF (13), redefining the "optimal" ablation approach started to appear mandatory. Our project (The PIVCO study) aims to determine a more standardized procedure representing optimal ablation strategy for patients suffering from PsAF using PFA and multielectrode ablation catheters. The central hypothesis is that ablation of the posterior LA wall (PWI), together with mitral and cavotricuspid isthmus ablation added on top of PVI, will be associated with better effects in terms of rhythm control. Given the speed, safety, and ease of standardization of ablation using electroporation, a demonstration of the superiority of either approach could significantly impact the current standard of clinical care.

Read the detailed description

Purpose Since a new method called pulsed-field ablation (PFA) has emerged, allowing significantly simpler, safer, and faster creation of ablative lesions in paroxysmal AF and PsAF (13), redefining the "optimal" ablation approach started to appear mandatory. Our project (The PIVCO study) aims to determine a more standardized procedure representing optimal ablation strategy for patients suffering from PsAF using PFA and multielectrode ablation catheters. The central hypothesis is that ablation of the posterior LA wall (PWI), together with mitral and cavotricuspid isthmus ablation added on top of PVI, will be associated with better effects in terms of rhythm control. Given the speed, safety, and ease of standardization of ablation using electroporation, a demonstration of the superiority of either approach could significantly impact the current standard of clinical care.

Primary endpoints

(1) The primary endpoint will be a recurrence of AF (or atrial tachycardia, AT) lasting >30 seconds as assessed using repeated 7-day ECG Holter monitoring in patients without anti-arrhythmic drugs (AADs) during the entire post-blanking follow-up, i.e., starting three months after the index procedure. All patients should complete a 12-month follow-up period.

Secondary endpoints

(1) The first recurrence of on-AADs AF/AT lasting >6 minutes during the post-blanking follow-up period (i.e., disregarding all off-AAD episodes). (2) Number of hospitalizations and emergency out-patient visits related to AF/AT recurrence, worsening of heart failure, or other cardiovascular diseases. (3) Number of electrical cardioversions. (4) Proportion of patients on AADs at the end of follow-up. (5) PFA-related complications. (6) Assessment of the quality of life using standardized instruments (AFEQT, EQ5D). (7) Feasibility of achieving a complete block of the mitral isthmus and PWI using PFA (8) Proportion of patients with delayed conduction into LAA after mitral line (9) Number of patients that underwent repeated ablations during follow-up.

Interventions

Procedures that will be performed on the day of admission for ablation:

  1. 12-lead ECG
  2. Randomization to group PVI or PVI+
  3. Physical examination
  4. Medication taken
  5. Medical history
  6. Laboratory tests (biochemistry - NTproBNP, K, urea, creatinine, ALT, AST, GMT, CRP; KO - Hb, leu, PLT)
  7. Cardiac CT scan as decided by the attending physician
  8. Transthoracic echocardiography (left atrial [LA] dimension in PLAX, LAVi, transverse and longitudinal LA dimension in A4CH, LA area in A4CH, left ventricular ejection fraction (LV EF), LV dimension in PLAX, estimation of PASP, quantification of any valvular defect
  9. Esophageal echocardiography (TEE) of the heart as decided by the attending physician to exclude intracardiac thrombosis
  10. Quality of life questionnaires (EQ5DY, AFEQT)

Catheter ablation strategy

In all patients, ablation will be performed by electroporation (Farapulse system), as recommended, with at least two applications per each ablation spot. Based on the randomization, patients will be treated using two distinct approaches:

Group PVI (Pulmonary vein isolation only)

  1. No ablation at the cavotricuspid isthmus (CTI)
  2. Transseptal puncture
  3. PVI (plus application to the superior anterior aspect of the right superior pulmonary vein [RSPV])
  4. In the absence of AF termination - cardioversion
  5. Induction - in case of persistent arrhythmia (regardless of regularity of activation in the atria) - cardioversion, without further ablation outside PVI

Group PVI+ (Complex ablation procedure)

  1. Transseptal puncture
  2. PVI (plus application to the superior anterior aspect of the RSPV)
  3. Roofline
  4. Box isolation of the posterior wall of the left atrium (line on the LA roof between left superior pulmonary vein [LSPV] and RSPV, the line between left inferior pulmonary vein [LIPV] and right inferior pulmonary vein [RIPV])
  5. Ablation along the coronary sinus (CS) from the endocardium, in the form of limited energy application in the left postero-septum
  6. Posterolateral mitral isthmus line
  7. In the absence of termination of AF to SR or when AF is converted to AT, cardioversion will be performed
  8. Verification and eventual completion of the bidirectional mitral line conduction block
  9. Ablation at CTI - completion of the bidirectional conduction block
  10. Induction (burst atrial pacing from proximal CS at different cycle lengths of 300 ms, 250 ms, and 200 ms, each step for 5-10 seconds; then RAMP pacing 300-200 ms)
  11. If AF or AT is induced, cardioversion will be performed

Follow-up The following information will be recorded on the day of discharge: Date of hospital discharge after ablation, length of in-hospital stays, early complications of ablation, and medication at the discharge (all antiarrhythmic drugs except beta-blockers will permanently be discontinued at hospital discharge).

Four 7-day Holter ECG monitoring recordings will be done at 3, 6, 9, and 12 months after ablation (in case of recurrence of AF after ablation, standard treatment according to the treating physician's decision, including the possibility of antiarrhythmic medication, electrical cardioversion or repeated ablation, will be applied).

A telephone visit be done at 1, 3, 6, and 9 months after ablation with an inquiry about complications of the ablation procedure, perceived recurrence of AF, use of antiarrhythmic and antithrombotic medication, elective cardioversion, hospitalization, and reasons for it.

An in-office visit will be done 12 months after ablation in the hospital's out-patient department, including an inquiry about complications of the ablation procedure, perceived and documented recurrence of AF, use of antiarrhythmic and antithrombotic medication, elective cardioversion, hospitalization and reasons for it after ablation, physical examination, medication history, ECG, echocardiography and quality of life questionnaires.

03

Conditions studied

  • Persistent Atrial Fibrillation
  • Pulsed-field Ablation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persistent or long-standing persistent AF proved on at least two 12-lead recordings more than one week apart or > 7-day EKG Holter recordings
  • Age ≥ 18 years at the time of study enrollment
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Paroxysmal AF
  • Sinus rhythm on the 12-lead on admission unless recent external electrical cardioversion was carried out within the last six months and the patient is treated by amiodarone
  • LA diameter > 55 mm (measured in the parasternal long-axis view)
  • History of AF ablation in the past
  • History of cardiac surgery
  • Significant valvular defect
  • Age below 18 years
  • Pregnancy, breastfeeding
  • Any disease with a \<1 year
  • Terminal renal failure
  • History of pacemaker or defibrillator implantation
  • Significant thyroid disease
  • Uncorrected congenital heart disease or valvular obstruction
  • Obstructive hypertrophic cardiomyopathy
  • Active myocarditis
  • Constrictive pericarditis
  • Untreated hypothyroidism or hyperthyroidism
  • Adrenal insufficiency
  • Active vasculitis due to collagen vascular disease
  • Presence on a heart transplant waiting list (UNOS category 1A or 1B or equivalent). Patients on a non-acute heart transplant waiting list (UNOS category 2 or 7 or equal) are eligible for inclusion in the study
  • Recipient of any major organ transplant (e.g., lung, liver, heart)
  • Patient who is undergoing or has undergone cytotoxic or cytostatic chemotherapy and radiation therapy for the treatment of within six months before randomization or clinical evidence of current malignancy, with the following exceptions: basal or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, prostate cancer (if the localized disease is stable, with life expectancy > 2.5 years in the opinion of the investigator)
  • positivity with a survival expectancy of less than five years due to HIV
  • Chronic kidney disease with \< 30 ml/min
  • Chronic dialysis treatment
  • Recent (within three months) self-reported history of alcoholism or illicit drug dependence
  • Any illness (e.g., psychiatric illness) or situation that, in the opinion of the investigator, could place the subject at significant risk, confound the results of the study, or significantly affect the subject's participation in the study
  • Unwillingness to participate.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
518 participants (actual)

Study arms

  • Active comparator
    PVI

    Pulmonary vein isolation

    Device: pulsed-field ablation

  • Experimental
    PVI+

    Pulmonary vein isolation supplemented by the additional lesions: left atrial posterior wall isolation, mitral and cavotricuspid isthmus lines

    Device: pulsed-field ablation

Interventions

  • Devicepulsed-field ablation

    application of pulsed-field energy for pulmonary vein isolation and linear ablations

06

What researchers measure

Primary outcomes

  1. Atrial fibrillation recurrence

    The primary endpoint will be a recurrence of AF (or atrial tachycardia, AT) lasting \>30 seconds as assessed using repeated 7-day ECG Holter monitoring in patients without anti-arrhythmic drugs (AADs) during the entire post-blanking follow-up, i.e., starting 60 days after the index procedure. All patients should complete a 12-month follow-up period.

    Time frame: Whole follow-up (up to 3 years)

Secondary outcomes

  1. Atrial fibrillation recurrence on AADs

    The first recurrence of on-AADs AF/AT lasting \>60 minutes during the post-blanking follow-up period (i.e., disregarding all off-AAD episodes).

    Time frame: Whole follow-up (up to 3 years)

  2. AF burden

    AF/AT burden (calculated as total time spent in arrhythmia over total monitoring time during the whole follow-up).

    Time frame: Whole follow-up (up to 3 years)

  3. AADs usage

    Number of patients using AADs at the end of follow-up.

    Time frame: At the last documented follow-up (up to 3 years)

  4. Hospitalization rate

    Number of hospitalisations for all reasons and related to AF/AT recurrence, worsening of heart failure, or other cardiovascular diseases.

    Time frame: Whole follow-up (up to 3 years)

  5. Cardioversion

    Number of electrical or pharmacological cardioversions.

    Time frame: Whole follow-up (up to 3 years)

  6. Complications

    PFA-related complications: composite of cardiac tamponade requiring drainage, persistent phrenic nerve palsy lasting more than 24 hours, persistent sinoatrial or atrioventricular block lasting more than 24 hours, major serious vascular complications requiring intervention or prolonging hospitalization, stroke or transient ischemic attack, atrioesophageal fistula, worsening of renal functions due to haemolysis, ST segment elevation or depression with hemodynamic instability, acute myocardial infarction or death within 90 days after ablation.

    Time frame: Within 90 days after ablation

  7. Atrial Fibrillation Effect on Quality of Life (AFEQT)

    Assessment of the quality of life using standardised instrument AFEQT. Three domains and global QoL will be assessed using a calculated score of 0 to 100% (100% = the best quality of life) based on the patient´s response to 20 questions.

    Time frame: 12 months following ablation procedure

  8. EuroQol Group questionnaire on quality of life

    Assessment of mobility, self-care, pain or discomfort, anxiety or depression by a Likert scale (1-3, 1 = no limitation, 3 = severe limitation) complemented by visual aid score (1-100, the higher score, the better quality of life).

    Time frame: 12 months following ablation procedure

07

Study locations

3 sites
  • Ceske Budejovice Hospital
    České Budějovice, 37001, Czechia
  • University Hospital
    Olomouc, 77900, Czechia
  • Institute for Clinical and Experimental Medicine
    Prague, 14037, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jul 2026, 37 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 37 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jun 2026 → Jul 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2023
First posted
Jun 28, 2023
StartActual
Jun 20, 2023
Primary completionActual
Jul 31, 2026was Jun 2026
CompletionActual
Oct 22, 2026was Nov 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Primary completion
Jun 30, 2026→Jul 31, 2026 (actual)
Oct 30, 2026
Study completion
Nov 30, 2026→Oct 22, 2026 (actual)
Oct 30, 2026
Enrollment
300 (estimated)→518 (actual)
Oct 30, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameAtrial fibrillation recurrence1 year following ablation procedure → Whole follow-up (up to 3 years)
  • DescriptionAtrial fibrillation recurrence: how it is measured was reworded
Oct 30, 2026
Secondary outcomes
6 time frame changed, 2 added, 4 description edited
What changed in the outcomes
  • AddedAF burdenTime frame: Whole follow-up (up to 3 years)
  • AddedAADs usageTime frame: At the last documented follow-up (up to 3 years)
  • Time frameAtrial fibrillation recurrence on AADs1 year following ablation procedure → Whole follow-up (up to 3 years)
  • Time frameHospitalization rate1 year following ablation procedure → Whole follow-up (up to 3 years)
  • Time frameCardioversion1 year following ablation procedure → Whole follow-up (up to 3 years)
  • Time frameComplications1 year following ablation procedure → Within 90 days after ablation
  • Time frameAtrial Fibrillation Effect on Quality of Life (AFEQT)1 year following ablation procedure → 12 months following ablation procedure
  • Time frameEuroQol Group questionnaire on quality of life1 year following ablation procedure → 12 months following ablation procedure
  • DescriptionAtrial fibrillation recurrence on AADs: how it is measured was reworded
  • DescriptionCardioversion: how it is measured was reworded
  • DescriptionComplications: how it is measured was reworded
  • DescriptionHospitalization rate: how it is measured was reworded
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Primary completion Jun 30, 2026→Jul 31, 2026 (now actual)
    Study completion Nov 30, 2026→Oct 22, 2026 (now actual)
    Enrollment 300 (estimated)→518 (actual)
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameAtrial fibrillation recurrence1 year following ablation procedure → Whole follow-up (up to 3 years)
    • DescriptionAtrial fibrillation recurrence: how it is measured was reworded
    Secondary outcomes 6 time frame changed, 2 added, 4 description edited
    What changed in the outcomes
    • AddedAF burdenTime frame: Whole follow-up (up to 3 years)
    • AddedAADs usageTime frame: At the last documented follow-up (up to 3 years)
    • Time frameAtrial fibrillation recurrence on AADs1 year following ablation procedure → Whole follow-up (up to 3 years)
    • Time frameHospitalization rate1 year following ablation procedure → Whole follow-up (up to 3 years)
    • Time frameCardioversion1 year following ablation procedure → Whole follow-up (up to 3 years)
    • Time frameComplications1 year following ablation procedure → Within 90 days after ablation
    • Time frameAtrial Fibrillation Effect on Quality of Life (AFEQT)1 year following ablation procedure → 12 months following ablation procedure
    • Time frameEuroQol Group questionnaire on quality of life1 year following ablation procedure → 12 months following ablation procedure
    • DescriptionAtrial fibrillation recurrence on AADs: how it is measured was reworded
    • DescriptionCardioversion: how it is measured was reworded
    • DescriptionComplications: how it is measured was reworded
    • DescriptionHospitalization rate: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05922917
Lead sponsor
České Budějovice Hospital
Collaborators
University Hospital Olomouc
Responsible party
Sponsor
First posted
Jun 28, 2023
Start date
Jun 20, 2023
Primary completion
Jul 31, 2026
Completion
Oct 22, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion